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Background: Gene therapeutic-delivered overexpression of P-
glycoprotein (P-gp), the product of MDR1 (multidrug resistance
1) gene, might protect normal tissue during chemo- and radio-
therapy of P-gp-expressing tumors. However, little is known
about the influence of MDR1-overexpression on the expression
of other genes.
Methods: Differentially gene expression in untransduced and
oncoretrovirally transduced human lymphoblastoid TK6 cells
were analysed by using the GeneChip Human Genome U133
Plus2.0 (Affymetrix). The expression of several genes was vali-
dated with quantitative real-time PCR (TaqMan; Applied Biosys-
tems). Radiation-induced apoptosis was analysed by the sub-G1
DNA content using flow cytometry. Cell survival was measured
by the colony formation assay.
Results: Sixty-one annotated genes showed a significant change
in expression (p < 104) in MDR1-overexpressing compared to
untransduced and control virus-transduced cells. Several genes
coding for proteins involved in detoxification and exocytosis (e.g.
ALDH1A, UNC13) were up-regulated. Additionally, proapoptotic
genes were down-regulated (e.g. CASP1, CASP4) with concomitant
increased expression of the potential antiapoptotic gene AKT3. In
functional assays overexpression of MDR1 conferred protection
against radiation-induced clonogenic inactivation and apoptosis.
Conclusion: The resistant phenotype of MDR1-mediated P-gp
overexpressing cells is associated with differential expression of
several genes coding for metabolic as well as pro- and antiapopto-
tic proteins. Our results could have important implications for
MDR1-gene therapy in patients receiving chemotherapy regimens
in combination with radiotherapy.
doi:10.1016/j.ejcsup.2006.04.079
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Background: BAFF, APRIL and TNFR-family members are involved
in various cancers including B cell malignancies. The aim of thestudy is to identify new therapeutic targets in multiple myeloma
using gene expression analysis.
Methods: Samples of 65 patients (CD138-purified myeloma cells
(MMC) and bone-marrow-microenvironment (BMME)), 7 normal
bone-marrow-plasma-cell-samples (BMPC), 7 in vitro generated
osteoclast-samples, and 20 human-myeloma-cell-lines were
investigated. The expression of TACI, BCMA and BAFFR and the
respective ligands BAFF and APRIL on MMC and BMSC was
assessed by quantitative RT-PCR and Affymetrix U133 A + B
DNA-microarrays. BMMAs of MM-patients were exposed to the
TACI-Fc5 fusion-protein (Serono) containing the extracellular
BAFF/APRIL-binding domain of TACI and the Fc-region of human
Immungobulin G, to neutralize BAFF and APRIL secreted by MMC/
BMME.
Results: MMC express TACI, the receptor of BAFF/APRIL. BAFF
and APRIL promote MMC growth. The main site of production
for BAFF and APRIL is the BMME, i.e. monocytes/neutrophils and
osteoclasts, respectively.1,2 The TACI-Fc5 fusion protein is cur-
rently under investigation in a clinical phase I/II trial at the Uni-
versity Hospitals of Montpellier and Heidelberg.
Conclusion: Inhibiting TACI-signaling via BAFF and APRIL by a
TACI-Fc5 fusion protein is a promising new therapeutic approach
in the treatment of MM.
doi:10.1016/j.ejcsup.2006.04.080
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Background: To test the ability of our EC-classification1,2 to (i)
predict EFS in 100 MM-patients treated with high-dose-chemo-
therapy and autologous-stem-cell-transplantation, (ii) investigate
whether the classification represents an independent prognostic
factor.
Methods: 128 newly-diagnosed MM-patients (65 training-group/
63 validation-group) were included. Bone-marrow aspirates
were CD138-purified and RNA subjected to Affymetrix HG
U133 A + B (training-group) and 2.0+ (validation-group) arrays.
CCND1-, CCND2- and FGFR3-expression were verified by RT-
PCR and Western-blotting. iFISH was performed for chromo-
somes 1q21, 11q23, 11q13, 13q14, 17p13, t(4;14) and t(11;14).
Expression data were gcrma-normalised and nearest-shrun-
ken-centroids applied to cross-validate a predictor on the train-
ing-group. Log-rank test and Cox-proportional-hazard-model
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dose-chemotherapy.
Results: Gene-expression and iFISH allow a molecular classifica-
tion of MM (expression-cytogenetic (EC) classification): (1.1)
CCND1-expression and 11q13+, (1.2) CCND1-expression, translo-
cations involving 11q13, (2.1) CCND2-overexpression without
11q13+, t(11;14), t(4;14), (2.2) CCND2-overexpression, t(4;14),
FGFR3-upregulation.
Conclusion: EC-groups defined by the predictor show a distinc-
tive pattern in gene expression and significantly different EFS.
EC-groups and B2M represent independent prognostic
parameters.1,2
doi:10.1016/j.ejcsup.2006.04.081
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Switzerland; 2Signature Diagnostics AG, Potsdam, Germany.Background: Classification of patient samples is an important
aspect of cancer diagnosis and treatment. Recent microarray
studies have shown that cancer classification by gene expression
profiling is feasible and provides clinicians with additional infor-
mation to choose the most appropriate forms of treatment.
Patients and Methods: A ‘‘genetic algorithm’’, using K-Nearest
Neighbour-Classification was used to identify diagnostically rele-
vant probe set combinations (classifier) to classify patients with
sporadic colorectal cancer into stages without nodal and distant
metastasis (UICC I/II) and patients with advanced CRC with nodal
and distant metastasis (UICC III/IV). The algorithm was feeded
with the 5% top and 5% bottom probe sets after statistical ranking
(Golub, Wilcoxon, foldchange).
Results: Thus 2228 probe sets have been used as a starting pool.
Discriminating probe set combinations have been identified in a
training data set and checked using a non-overlapping test set.
Probe sets classifying correctly in more than 99% could be identi-
fied for tumor vs. normal tissue distinction and for UICC I/II vs.
III/IV distinction in the training set. In non-overlapping test-set
tumor/normal classifier performed well (90%), whereas UICC clas-
sifier only reached 60% performance.
Conclusion: Most likely generalization properties of the signa-
tures are poor because data representativeness is not sufficient
using this approach. Sample number is quite appropriate to iden-
tify differentially expressed genes between tumor and normal tis-
sues but it is likely to be insufficient to reliably reveal
differentially expressed genes between diverse prognostic stages
based on UICC classification in colorectal cancer.
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A transcript containing the long terminal repeat (LTR) and the
sequence homologous to the KIAA1245 mRNA fragment were
revealed among the transcribed LTRs of human endogenous
viruses of the K family in normal and tumor tissues. Ten other
sequences with a high level of homology to the KIAA1245 mRNA
were found in the GenBank. The intron-exon structures were
determined for all the sequences, and their exon sequences were
compared. The comparison showed that they differ both in the
extent of the exon homology and in the presence or absence of
the HERV-K LTR in the second intron. The revealed sequences
form a new gene family that comprises at least four subfamilies.
Two of these subfamilies have the LTR, and the other two do not.
We showed by PCR that the LTR was integrated into the introns
after the divergence of the orangutan evolutionary branch from
other hominoids but before the divergence of the gorilla branch,
i.e., 8–13 million years ago. The total expression of the genes of
this family was examined in a number of tissues. It was shown
that LTR-containing genes of this family expressed in tumor,
embryonic tissues and in transformed human cell cultures, in
explored normal tissues of the mature organism the expression
of genes of this family was not detected.
doi:10.1016/j.ejcsup.2006.04.083
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THEIR BIOLOGIC RELEVANCE
M. Duchrow, D. Maaser, A. Wehrstedt, J.K. Habermann, U.J.
Roblick, H.P. Bruch. Surgical Research Laboratory, Surgical Clinic,
University Clinic of Schleswig-Holstein, Campus Lu¨beck, Germany.
Background: Monoclonal antibody Ki-67 is a well-established
and widely used marker to access cell proliferation activity, par-
ticularly in tumors. Ki-67 is directed against a nuclear antigen
(pKi-67) which is solely expressed in actively proliferating cells
during all phases of the cell cycle, but it is absent in quiescent
cells. To investigate polymorphisms or mutations of the pKi-67
promoter we sequenced the promoter region of the pKi-67 gene
of 50 colorectal cancer patients and 24 healthy donors. To find dif-
ferences in the biologic relevance of polymorphisms we mea-
sured the promoter-activity of all detected variants.
Methods: The pKi-67 promoter region was amplified using Pfu-
polymerase, randomly cloned into the pCR-Blunt II-Topo-vector,
and cycle-sequenced using Thermosequenase. Firefly-luciferase
reporter plasmids were constructed by subcloning of the
sequence-controlled inserts into the pGL3-Basic-vector. The
activity of the reporter plasmids was measured using the Dual-
Luciferase Reporter Assay.
Results: After comparison of the cloned promoter sequences we
found four polymorphisms (three SNPs and one tetranucleotide
repeat) at position -518(A > G), -351(T > C), 186((GGGC)3 > (GGGC)5),
